Health ❯ Healthcare ❯ Patient Care

Treatment Options

Oral Medications Innovative Therapies Subcutaneous Administration Personalized Medicine Combination Therapy Chemotherapy Endocrine Therapy Cognitive Impairment Targeted Therapy Immunotherapy

3 ARTICLES

14h ago

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

A European Commission decision and publication of official prescribing information are required before the refillable ranibizumab implant can be used by trained vitreoretinal surgeons.

Stories older than 24h

3 ARTICLES

5d ago

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL Cholesterol

31 ARTICLES

6d ago

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

5 ARTICLES

last wk.

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

7 ARTICLES

last wk.

FDA Approves At‑Home Weekly Subcutaneous Starter Dose for Leqembi

18 ARTICLES

last wk.

Late‑Stage Trial of Wainua Misses Primary Goal in ATTR‑CM Study

8 ARTICLES

3w ago

Melatonin Lowers Chronic Musculoskeletal Pain, University of Sydney Analysis Finds

3 ARTICLES

3w ago

FDA Grants Priority Review to Roche’s Enspryng for Thyroid Eye Disease

3 ARTICLES

3w ago

FDA Approves Lumvoa for Thyroid Eye Disease

3 ARTICLES

4w ago

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

3 ARTICLES

last mo.

IGeL‑Monitor Finds No Clear Benefit From Osteopathy for Lower Back Pain

3 ARTICLES

last mo.

FDA Approves First Generic Single‑Dose Flu Drug

4 ARTICLES

last mo.

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

5 ARTICLES

last mo.

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

6 ARTICLES

last mo.

NHS to Roll Out Five-Session Precision Radiotherapy for Early Prostate Cancer

3 ARTICLES

last mo.

UCSF Study Identifies Cellular Loop That Weakens Brain Aneurysms

3 ARTICLES

last mo.

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

4 ARTICLES

last mo.

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

4 ARTICLES

last mo.

EU Clears Sanofi’s Sarclisa for Subcutaneous Use With Portable Injector

4 ARTICLES

last mo.

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

Treatment Options

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL Cholesterol

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

FDA Approves At‑Home Weekly Subcutaneous Starter Dose for Leqembi

Late‑Stage Trial of Wainua Misses Primary Goal in ATTR‑CM Study

Melatonin Lowers Chronic Musculoskeletal Pain, University of Sydney Analysis Finds

FDA Grants Priority Review to Roche’s Enspryng for Thyroid Eye Disease

FDA Approves Lumvoa for Thyroid Eye Disease

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

Never miss stories about

Treatment Options

IGeL‑Monitor Finds No Clear Benefit From Osteopathy for Lower Back Pain

FDA Approves First Generic Single‑Dose Flu Drug

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

NHS to Roll Out Five-Session Precision Radiotherapy for Early Prostate Cancer

UCSF Study Identifies Cellular Loop That Weakens Brain Aneurysms

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

EU Clears Sanofi’s Sarclisa for Subcutaneous Use With Portable Injector

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

Never miss stories about

Treatment Options